-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that the recombinant respiratory syncytial virus (RSV) vaccine (SYS6057) developed by the Group has been approved by the China Drug Administration and can conduct clinical trials in China.

Zhitongcaijing·07/31/2026 10:01:05
Listen to the news
According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that the recombinant respiratory syncytial virus (RSV) vaccine (SYS6057) developed by the Group has been approved by the China Drug Administration and can conduct clinical trials in China.